Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CTGF


Brief Information

Name:Connective tissue growth factor
Target Synonym:Cellular communication network factor 2,IBP-8,Hypertrophic chondrocyte-specific protein 24,IGF-binding protein 8,IGFBP-8,Connective tissue growth factor,IGFBP8,CCN2,Insulin-like growth factor-binding protein 8,HCS24,CCN family member 2,CTGF,NOV2
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Loaded Monoclonal Anti-Human CTGF Antibody, Human IgG1 on AHC Biosensor, can bind Mouse CTGF, His Tag (Cat. No. CTF-M52Hc) with an affinity constant of 2.46 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Monoclonal Anti-Human CTGF Antibody, Human IgG1 on AHC Biosensor, can bind Human CTGF, His Tag (Cat. No. CTF-H52H5) with an affinity constant of 6.29 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CCN2,NOV2,HCS24,IGFBP8,IBP-8,IGFBP-8,IGF-binding protein 8


Connective Tissue Growth Factor (CTGF), also known as CCN2, is a member of the CCN (CCN1-6) family of modular matricellular proteins. Like other CCN proteins, mature human CTGF consists of IGF-binding protein domain, a vWF-C domain, a TSP-1 domain, and a cysteine knot heparin-binding domain. CTGF promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis. Analysis of CCN2 function in vivo has focused primarily on its key role as a mediator of excess ECM synthesis in multiple fibrotic diseases.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Penicillamine Approved Valeant Distamine, Pemine, Trisorcin, Cuprimine, Cupramine, Trolovol United States Hepatolenticular Degeneration; Cystinuria; Arthritis, Rheumatoid Valeant Pharmaceuticals International Inc 1970-12-04 Heavy Metal Poisoning; Arthritis, Rheumatoid; Hepatolenticular Degeneration; Cystinuria; Lead Poisoning Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Pamrevlumab FG-3019 Phase 3 Clinical Fibrogen Inc Diabetes Mellitus, Type 2; Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Liver Cirrhosis; Glomerulosclerosis, Focal Segmental; Muscular Dystrophy, Duchenne; Diabetic Nephropathies; Diabetes Mellitus Details
OLX-10010 cp-asiCTGF; OLX-101A; OLX-10010; BMT-101; OLX-101 Phase 2 Clinical Olix Pharmaceuticals Inc Pulmonary Fibrosis; Wet Macular Degeneration; Cicatrix, Hypertrophic; Macular Degeneration Details
SHR-1906 SHR-1906 Phase 2 Clinical Guangdong Hengrui Pharmaceutical Co Ltd Idiopathic Pulmonary Fibrosis Details
PRS-220 PRS-220 Phase 1 Clinical Pieris Pharmaceuticals Idiopathic Pulmonary Fibrosis Details
LEM-S401 LEM-S401; LEMS401 Phase 1 Clinical Lemonex Inc Cicatrix Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message